Investments · Diagnostics (cancer blood tests)
SoftBank leads $360 million round in cancer blood test company Guardant Health
- Investor
- SoftBank Group (Tokyo)
- In
- Guardant Health, Redwood City, California
- Value
- $360M round
- Status
- Announced on May 11, 2017; the round has closed.
- Date
- 2017-05-11
SoftBank Group led a $360 million funding round in Guardant Health, a Redwood City, California company that develops blood tests to detect and track cancer. The two also planned a joint venture to offer Guardant's tests in Asia, the Middle East and Africa.
Why it matters
The round was one of SoftBank's early large investments in US health technology, paired with a plan to take the tests to markets outside the US.
Sources
Kakehashi M&A News home
